Akero Therapeutics (AKRO) Institutional Ownership

During the previous two years, 185 institutional investors and hedge funds held shares of Akero Therapeutics. The most heavily invested institutionals were Wellington Management Group LLP ($205.23M), RTW Investments LP ($190.84M), Janus Henderson Group PLC ($167.77M), Price T Rowe Associates Inc. MD ($120.24M), Vanguard Group Inc. ($103.06M), Adage Capital Partners GP L.L.C. ($98.28M), and General Atlantic L.P. ($83.38M).Learn more on AKRO's institutional investors.

Of the 152 institutional investors that purchased Akero Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Wellington Management Group LLP ($5.12M), RTW Investments LP ($5.02M), Janus Henderson Group PLC ($2.02M), General Atlantic L.P. ($1.79M), Perceptive Advisors LLC ($1.53M), Point72 Asset Management L.P. ($1.30M), and Commodore Capital LP ($1.14M).

Institutional investors have bought a total of 34,061,511 shares in the last 24 months. This purchase volume represents approximately $1.10B in transactions.

Of the 83 institutional investors that sold Akero Therapeutics stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Skorpios Trust ($1.65M), Alkeon Capital Management LLC ($1.57M), Perceptive Advisors LLC ($1.45M), Fred Alger Management LLC ($1.22M), Adage Capital Partners GP L.L.C. ($1.11M), Janus Henderson Group PLC ($1.04M), and Avidity Partners Management LP ($790K).

Institutional investors have sold a total of 14,979,635 shares in the last 24 months. This volume of shares sold represents approximately $482.17M in transactions.